BioCentury | Apr 29, 2013
Strategy

Zerhouni's progress report

...and large mergers, including a merger encouraged by the French government between Aventis S.A. and Sanofi-Synthelabo S.A....
...research organization. In 1999, the two French companies Sanofi S.A. and Synthelabo merged to form Sanofi-Synthelabo S.A....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...a total of $90 billion over that time. The 2001-03 tallies include 13 companies, capturing Sanofi-Synthelabo...
...average number of shares outstanding and the average share price per year. Market cap for Sanofi-Synthelabo...
BioCentury | Dec 4, 2006
Company News

Newron board of directors update

Newron Pharmaceuticals S.p.A. , Bresso, Italy Business: Neurology Appointed: Herve Guerin, former vice chairman and COO of Sanofi Synthelabo Inc., now part of sanofi-aventis Group WIR Staff...
BioCentury | Sep 4, 2006
Strategy

Back to School 2006: Value for money

Thirteen years ago BioCentury sketched a picture called "The Clear Route to ROI" to depict the gap between the perceptions of value creation held by biotechnology companies and those of investors. Today a more mature...
BioCentury | Nov 14, 2005
Strategy

Serono: The whole vs. the parts

...the same kind of nationalistic stance that the French government took to the acquisition of Sanofi-Synthelabo S.A....
BioCentury | Nov 14, 2005
Company News

FibroGen management update

...Russell Ellison as VP of clinical development, formerly VP of medical affairs and CMO at Sanofi-Synthelabo S.A. WIR...
BioCentury | Aug 1, 2005
Company News

Enobia Phase Inc. board of directors update

Enobia Phase Inc. , Montreal, Quebec Business: Musculoskeletal Appointed: Yvon Bastien, formerly president of sanofi-aventis Group's Sanofi Synthelabo Canada unit; Sylvie Bouchard, VP of clinical development and regulatory affairs at Labopharm Inc.; Max Felhmann, CEO of...
BioCentury | Jun 20, 2005
Strategy

PharM&A

...$1.3B, securing rights to Igen's Origen electrochemiluminescence technology used in Roche's Elecsys diagnostics line 2004 Sanofi-Synthelabo...
BioCentury | Feb 21, 2005
Company News

Cerep SA, sanofi-aventis deal

Cerep will synthesize and supply SAN's Sanofi- Synthelabo Recherche subsidiary with custom compound libraries. Separately, Cerep and SAN extended through 2005 their 1997 deal to identify a compound for an undisclosed indication. Cerep SA (NM:Cerep),...
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...Sequus (now part of Johnson & Johnson) 3 (176) Eloxatin oxaliplatin Metastatic colorectal carcinoma 8/9/02 Sanofi-Synthelabo...
Items per page:
1 - 10 of 266
BioCentury | Apr 29, 2013
Strategy

Zerhouni's progress report

...and large mergers, including a merger encouraged by the French government between Aventis S.A. and Sanofi-Synthelabo S.A....
...research organization. In 1999, the two French companies Sanofi S.A. and Synthelabo merged to form Sanofi-Synthelabo S.A....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...a total of $90 billion over that time. The 2001-03 tallies include 13 companies, capturing Sanofi-Synthelabo...
...average number of shares outstanding and the average share price per year. Market cap for Sanofi-Synthelabo...
BioCentury | Dec 4, 2006
Company News

Newron board of directors update

Newron Pharmaceuticals S.p.A. , Bresso, Italy Business: Neurology Appointed: Herve Guerin, former vice chairman and COO of Sanofi Synthelabo Inc., now part of sanofi-aventis Group WIR Staff...
BioCentury | Sep 4, 2006
Strategy

Back to School 2006: Value for money

Thirteen years ago BioCentury sketched a picture called "The Clear Route to ROI" to depict the gap between the perceptions of value creation held by biotechnology companies and those of investors. Today a more mature...
BioCentury | Nov 14, 2005
Strategy

Serono: The whole vs. the parts

...the same kind of nationalistic stance that the French government took to the acquisition of Sanofi-Synthelabo S.A....
BioCentury | Nov 14, 2005
Company News

FibroGen management update

...Russell Ellison as VP of clinical development, formerly VP of medical affairs and CMO at Sanofi-Synthelabo S.A. WIR...
BioCentury | Aug 1, 2005
Company News

Enobia Phase Inc. board of directors update

Enobia Phase Inc. , Montreal, Quebec Business: Musculoskeletal Appointed: Yvon Bastien, formerly president of sanofi-aventis Group's Sanofi Synthelabo Canada unit; Sylvie Bouchard, VP of clinical development and regulatory affairs at Labopharm Inc.; Max Felhmann, CEO of...
BioCentury | Jun 20, 2005
Strategy

PharM&A

...$1.3B, securing rights to Igen's Origen electrochemiluminescence technology used in Roche's Elecsys diagnostics line 2004 Sanofi-Synthelabo...
BioCentury | Feb 21, 2005
Company News

Cerep SA, sanofi-aventis deal

Cerep will synthesize and supply SAN's Sanofi- Synthelabo Recherche subsidiary with custom compound libraries. Separately, Cerep and SAN extended through 2005 their 1997 deal to identify a compound for an undisclosed indication. Cerep SA (NM:Cerep),...
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...Sequus (now part of Johnson & Johnson) 3 (176) Eloxatin oxaliplatin Metastatic colorectal carcinoma 8/9/02 Sanofi-Synthelabo...
Items per page:
1 - 10 of 266